Literature DB >> 22896693

The pancreas cancer microenvironment.

Christine Feig1, Aarthi Gopinathan, Albrecht Neesse, Derek S Chan, Natalie Cook, David A Tuveson.   

Abstract

Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in more than 250,000 deaths per year worldwide. Despite extensive efforts, cytotoxic and targeted therapies have provided only limited efficacy for patients with PDA to date. One contributing factor to the failure of systemic therapies may be the abundant tumor stromal content that is the characteristic of PDA. The PDA stroma, aptly termed the tumor microenvironment, occupies the majority of the tumor mass, and consists of a dynamic assortment of extracellular matrix components and nonneoplastic cells including fibroblastic, vascular, and immune cells. Recent work has revealed that the PDA stroma supports tumor growth and promotes metastasis and simultaneously serves as a physical barrier to drug delivery. Accordingly, methods that alter stromal composition or function, for instance interference with the vasculature via Notch/Hedgehog pathway inhibition or relief of vascular compression by hyaluronidase, are under active investigation. Here, we will review our current understanding of the PDA tumor microenvironment, and highlight opportunities for further exploration that may benefit patients.

Entities:  

Mesh:

Year:  2012        PMID: 22896693      PMCID: PMC3442232          DOI: 10.1158/1078-0432.CCR-11-3114

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  104 in total

Review 1.  Adjuvant treatment of pancreatic cancer.

Authors:  John P Neoptolemos
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

Review 2.  The pancreatic stellate cell: a star on the rise in pancreatic diseases.

Authors:  M Bishr Omary; Aurelia Lugea; Anson W Lowe; Stephen J Pandol
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 3.  Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.

Authors:  William A Denny
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

4.  Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine.

Authors:  Ralf Jesnowski; Daniel Fürst; Jörg Ringel; Ying Chen; Andrea Schrödel; Jörg Kleeff; Armin Kolb; Wolfgang D Schareck; Matthias Löhr
Journal:  Lab Invest       Date:  2005-10       Impact factor: 5.662

5.  Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells.

Authors:  Shin Hamada; Atsushi Masamune; Tetsuya Takikawa; Noriaki Suzuki; Kazuhiro Kikuta; Morihisa Hirota; Hirofumi Hamada; Masayoshi Kobune; Kennichi Satoh; Tooru Shimosegawa
Journal:  Biochem Biophys Res Commun       Date:  2012-04-09       Impact factor: 3.575

6.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

7.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells.

Authors:  Alain Vonlaufen; Swapna Joshi; Changfa Qu; Phoebe A Phillips; Zhihong Xu; Nicole R Parker; Cheryl S Toi; Romano C Pirola; Jeremy S Wilson; David Goldstein; Minoti V Apte
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  Sonic hedgehog promotes desmoplasia in pancreatic cancer.

Authors:  Jennifer M Bailey; Benjamin J Swanson; Tomofumi Hamada; John P Eggers; Pankaj K Singh; Thomas Caffery; Michel M Ouellette; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

9.  Expression pattern and circulating levels of endostatin in patients with pancreas cancer.

Authors:  Daniel Ohlund; Bjarne Ardnor; Mikael Oman; Peter Naredi; Malin Sund
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

10.  Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.

Authors:  J Itakura; T Ishiwata; H Friess; H Fujii; Y Matsumoto; M W Büchler; M Korc
Journal:  Clin Cancer Res       Date:  1997-08       Impact factor: 12.531

View more
  526 in total

1.  Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.

Authors:  Kyoung Eun Lee; Michelle Spata; Lauren J Bayne; Elizabeth L Buza; Amy C Durham; David Allman; Robert H Vonderheide; M Celeste Simon
Journal:  Cancer Discov       Date:  2015-12-29       Impact factor: 39.397

Review 2.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 3.  Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.

Authors:  Lei Miao; C Michael Lin; Leaf Huang
Journal:  J Control Release       Date:  2015-08-12       Impact factor: 9.776

Review 4.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 5.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

6.  The Orai Ca2+ channel inhibitor CM4620 targets both parenchymal and immune cells to reduce inflammation in experimental acute pancreatitis.

Authors:  Richard T Waldron; Yafeng Chen; Hung Pham; Ariel Go; Hsin-Yuan Su; Cheng Hu; Li Wen; Sohail Z Husain; Catherine A Sugar; Jack Roos; Stephanie Ramos; Aurelia Lugea; Michael Dunn; Kenneth Stauderman; Stephen J Pandol
Journal:  J Physiol       Date:  2019-05-22       Impact factor: 5.182

Review 7.  Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Authors:  Vishal Jindal; Ena Arora; Muhammad Masab; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

8.  Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.

Authors:  Neus Martínez-Bosch; Maite G Fernández-Barrena; Mireia Moreno; Elena Ortiz-Zapater; Jessica Munné-Collado; Mar Iglesias; Sabine André; Hans-Joachim Gabius; Rosa F Hwang; Françoise Poirier; Carolina Navas; Carmen Guerra; Martin E Fernández-Zapico; Pilar Navarro
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

Review 9.  Immune Therapy in GI Malignancies: A Review.

Authors:  Judy Wang; Kim A Reiss; Rina Khatri; Elizabeth Jaffee; Dan Laheru
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

10.  Sonic advance: CCN1 regulates sonic hedgehog in pancreatic cancer.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2012-12-20       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.